1. Home
  2. News
  3. Invex Therapeutics Ltd.
  4. Invex Granted European Patent for Exenatide in Hydrocephalus
More Invex Therapeutics Ltd. news
Invex Therapeutics Ltd.ASX: IXC

Invex Granted European Patent for Exenatide in Hydrocephalus

Nov 21, 2023 at 9:34 PM EST · Issued by Invex Therapeutics Ltd.

Filed with ASX · Nov 21, 2023 at 9:34 PM EST · 2 pages · English

On 6ix: 6ix.com/news/invex-granted-european-patent-for-exenatide-in-hydrocephalus

Invex Therapeutics Ltd. on 6ix

Story so far

  • Invex Granted Key European Patent for ExenatideAug 16, 2021

Earlier from Invex Therapeutics

  • Proposed Capital Return to Shareholders of $14.0 MillionNov 1, 2023
  • Invex issued US patent for Traumatic Brain InjuryAug 23, 2023
  • Invex to close IIH Evolve Phase III Clinical TrialAug 20, 2023
  • Phase III Clinical Trial Update and New IIH Market AnalysisJun 27, 2023
  • Invex Granted European Orphan Drug Designation for TBIJun 22, 2023

Later from Invex Therapeutics

  • Invex and Peptron Mutually Terminate Manufacturing AgreementDec 21, 2023
  • Appendix 4D and Half year reportFeb 15, 2024
  • ATO Class Ruling Return of CapitalMar 20, 2024
  • Invex receives R&D Tax RebateJun 21, 2024
  • Quarterly Activities Report and Appendix 4COct 7, 2024
All Invex Therapeutics news releases↗

Follow Invex Therapeutics into a list and get an email when it puts out news.

Follow Invex Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer